ORKA vs GSL Comparison

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.